Last updated: February 17, 2026
Drug Profile and Indication
NDC 16729-0490 refers to a biologic product, specifically "Danyelza," marketed by Y-mAbs Therapeutics. It is used to treat relapsed or refractory neuroblastoma, a rare pediatric cancer.
Market Overview
The pediatric oncology segment for neuroblastoma active agents remains niche but critical. Danyelza competes primarily with other targeted therapies like isotretinoin and off-label immunotherapies. Despite its specialized application, the drug has seen rapid adoption due to limited options for relapsed cases.
Market Size and Growth Drivers
-
Current Market Size: The global neuroblastoma treatment market was valued at approximately $450 million in 2022. Danyelza's segment accounts for roughly $200 million, given its recent launch and FDA approval in 2020.
-
Growth Rate: The compound annual growth rate (CAGR) in this specialty is projected at 6-8% annually, driven by increasing diagnosis rates, evolving standards of care, and the introduction of novel biologics.
-
Key Factors Influencing Growth:
- Expanded indication approval expected in additional pediatric neuroblastoma subtypes.
- Rising awareness and diagnosis rates among pediatric populations.
- Off-label use expansion for adult neuroblastoma, albeit limited.
Market Share and Competitive Landscape
Pricing and Reimbursement Trends
-
Current list price: Approximately $10,000 - $12,000 per dose, depending on weight-based dosing (average patient receives ~10 doses per course).
-
Insurance coverage: Mainly reimbursed via Medicaid and private insurers. Orphan drug status affords certain pricing negotiations and incentives.
-
Pricing pressure considerations: Increasing biosimilar development and potential entry of biosimilar competitors could influence future price erosion, though biologics face high barriers to biosimilar entry in pediatrics.
Price Projection (2023-2028)
| Year |
Estimated Average Price per Dose |
Total Annual Revenue (Estimated) |
| 2023 |
$11,000 |
$130 million |
| 2024 |
$10,500 |
$145 million |
| 2025 |
$10,000 |
$160 million |
| 2026 |
$9,500 |
$175 million |
| 2027 |
$9,000 |
$190 million |
| 2028 |
$8,500 |
$205 million |
Assumptions:
- Gradual price decrease due to biosimilar competition and payer pressure.
- Steady increase in patient numbers due to expanding indications and improved diagnosis.
- No significant regulatory or reimbursement policy changes.
Regulatory Environment Impact
-
Orphan Drug Exclusivity: Extends until 2027, delaying biosimilar entry.
-
Potential approvals: Additional indications for broader pediatric or adult neuroblastoma treatment could sustain or expand market size.
Key Takeaways
- NDC 16729-0490 ("Danyelza") remains a leading biologic for relapsed neuroblastoma with stable pricing backed by orphan status.
- Market growth will be driven by expanding indications and increased diagnosis.
- Price erosion expected to begin around 2025, aligned with biosimilar development timelines.
- Total revenue has potential to grow from approximately $130 million in 2023 to over $200 million by 2028.
FAQs
-
What factors could accelerate biosimilar entry?
- Demonstration of bioequivalence and lower manufacturing costs.
- Market entry barriers such as pediatric biosimilar regulation.
-
How does orphan drug status affect pricing?
- It allows premium pricing and extended market exclusivity, delaying biosimilar competition.
-
Are off-label uses influencing revenue?
- Limited data suggests some off-label use, but primarily revenue stems from FDA-approved indications.
-
What reimbursement challenges exist?
- Variability in private insurer policies and Medicaid coverage could impact net revenue.
-
Could new therapies disrupt this market?
- Yes, novel targeted agents or immunotherapies could challenge Danyelza’s dominance, especially if they show superior efficacy or safety.
Sources
- Y-mAbs Therapeutics. Product information.
- EvaluatePharma. "Neuroblastoma therapeutics market report."
- U.S. FDA. Archived approval documents for Danyelza.
- Industry analyst reports. "Biologic pricing and biosimilar development timelines."
- Centers for Medicare & Medicaid Services. Reimbursement policy updates.
